knowledge -WSS

knowledge

author：knowledge 2025-09-29 20:17:39 - browse：54

Jamy Ard (left) and Robert Lustig (right) on the 2023 STAT Breakthrough Summit stage -- coverage from STAT — Obesity experts Jamy Ard (left) and Robert Lustig speak at a panel during the 2023 STAT Breakthrough Summit. Sarah Gonzalez for STAT

Amid rising demand for drugs like Wegovy, Ozempic, and Mounjaro that can lead to significant weight loss, some obesity experts are concerned about the drugs’ costs — both to patients’ finances and to their health.

Speaking at a panel on new obesity treatments at the STAT Breakthrough Summit in San Francisco on Thursday, one expert cited a large clinical trial for Wegovy that showed that about 40% of the weight participants lost was lean mass. Side effects like nausea, vomiting, and a possible link to rare cases of pancreatitis also still plague this newest class of drugs, which imitate the effects of a hormone called glucagon-like peptide 1 (GLP) that helps people feel full.

“That’s what starvation does. You lose equal amounts of muscle and fat,” said Robert Lustig, emeritus professor of pediatrics at the University of California, San Francisco. “If you’re a person 60 years old or over and you’re losing muscle, your risk of dying just went up exponentially. So we may be … robbing Peter to pay Paul.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Merck, Daiichi strike cancer drug pact worth up to $22 billion

hotspot

knowledge

WSS

STAT Summit: How researchers deal with rejection

STAT Summit: Meghan O’Rourke on making chronic illness visible

Health tech investors get more selective as pandemic boom fades

CZI to create biohub to build anti

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

FDA clears Verve to begin U.S. study of gene

focus

knowledge

leisure time

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Bring on the sabbaticals for nurses

New air purifier tech could be key to improving indoor air quality

Readout Newsletter: Illumina, CRISPR, Regeneron

Affirmative action in medical school literally saved lives

6 surprising facts about sugar

DIEP, the 'gold standard' of breast reconstruction, is under threat

Asbestos ban is immediate, but health effects will linger for decades

Drug repurposing or repositioning? The language matters

Mirador, a new biotech startup, launches with $400 million

leisure time

Readout LOUD podcast, live from the STAT Breakthrough Summit East

STAT Readout: Friday, Oct. 20 biotech updates

Study on Amgen’s bispecific immunotherapy produces positive data

Roche drug slashes death risk in early

This gene therapy has record $4.25 million price. It's saved children.

CRISPR technology availability, affordability needs to be expanded

focus

hotspot

knowledge

explore